Cannabis Law Report

MAY 29, 2022

Celebrated author Michael Pollan has published two bestselling books on the topic: How to Change Your Mind and This is Your Mind on Plants. 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. In 2017, FDA granted a request for Breakthrough Therapy designation for MDMA to treat PTSD.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. In 2017, the FDA designated MDMA a breakthrough therapy for PTSD.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

JANUARY 11, 2019

Accordingly, the Drug Enforcement Administration (DEA) no longer has any claim to interfere with the interstate commerce of hemp products, so as long as the THC level is at or below 0.3%. While the DEA is now officially out of the hemp regulation business, the U.S. The FDA’s position on CBD is unsettled and unsupported by law.

Hemp 49

Hemp CBD Law Seed-To-Sale 49

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. IMAJ, FEBRUARY 2017.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73